Literature DB >> 2584700

Perforin mRNA in primary peritoneal exudate cytotoxic T lymphocytes.

C Nagler-Anderson1, M Lichtenheld, H N Eisen, E R Podack.   

Abstract

Considerable evidence indicates that cloned CTL cell lines kill target cells by releasing toxic granules that contain a cytolytic protein, called perforin, and several serine esterases (granzymes A to F). However, primary CTL, such as the highly cytolytic peritoneal exudate lymphocyte (PEL) cell population, have been found by a hemolytic assay to have no perforin, or perhaps only borderline levels of that protein, suggesting that these cells use a different lytic mechanism. To determine whether or not primary CTL express the perforin gene, we have here compared mRNA from PEL CTL and from a cloned CTL cell line, 2C, by Northern blot analysis using a perforin cDNA probe. CD8+ PEL CTL contain approximately 30% of the amount of perforin message present in 2C. Moreover, depletion of CD8+ T cells from the total peritoneal exudate cell population removes both cytolytic activity and perforin message. We have previously shown that PEL CTL elicit the same changes in target cells as cloned CTL cell lines and are resistant to lysis by the toxic granules purified from these cells lines. Taken together these results are consistent with the view that primary CTL, as well as long term cloned CTL cell lines, exercise their cytolytic activity by means of perforin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2584700

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  In situ detection of activated cytotoxic cells in follicular lymphomas.

Authors:  M B Leger-Ravet; O Devergne; M Peuchmaur; P Solal-Celigny; N Brousse; P Gaulard; P Galanaud; D Emilie
Journal:  Am J Pathol       Date:  1994-03       Impact factor: 4.307

2.  Target cell death triggered by cytotoxic T lymphocytes: a target cell mutant distinguishes passive pore formation and active cell suicide mechanisms.

Authors:  D S Ucker; J D Wilson; L D Hebshi
Journal:  Mol Cell Biol       Date:  1994-01       Impact factor: 4.272

3.  Mechanisms whereby cytotoxic T lymphocytes damage guinea-pig ventricular myocytes in vitro.

Authors:  B Felzen; G Berke; D Rosen; O Binah
Journal:  Pflugers Arch       Date:  1994-07       Impact factor: 3.657

4.  Perforin mRNA expression in the inflamed tissues of NZB/W F1 lupus mice decreases with methylprednisolone treatment.

Authors:  T Nakamura; I Ebihara; Y Tomino; K Okumura; H Koide
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

5.  Mechanism of lymphocyte-mediated cytolysis: functional cytolytic T cells lacking perforin and granzymes.

Authors:  G Berke; D Rosen; D Ronen
Journal:  Immunology       Date:  1993-01       Impact factor: 7.397

6.  Characterization of a novel monoclonal antibody against human perforin using transfected cell lines.

Authors:  B C Schlesinger; L Cheng
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

7.  Cytotoxic potential of intraepithelial lymphocytes (IELs). Presence of TIA-1, the cytolytic granule-associated protein, in human IELs in normal and diseased intestine.

Authors:  G J Russell; C Nagler-Anderson; P Anderson; A K Bhan
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

8.  Switch from perforin-expressing to perforin-deficient CD8(+) T cells accounts for two distinct types of effector cytotoxic T lymphocytes in vivo.

Authors:  Avihai Meiraz; Orit Gal Garber; Shaul Harari; David Hassin; Gideon Berke
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

9.  Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes.

Authors:  P J Peters; J Borst; V Oorschot; M Fukuda; O Krähenbühl; J Tschopp; J W Slot; H J Geuze
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

10.  T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism.

Authors:  D J Moss; S R Burrows; G D Baxter; M F Lavin
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.